
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a drug called AZD4547 for that have continued to grow despite all other current
.
Doctors use treatments such as surgery, radiotherapy, chemotherapy, hormone therapy and biological therapy to treat cancer. But sometimes cancers continue to grow despite having all the standard treatments. Researchers are looking for new drugs to help people in this situation. In this trial, they are looking at a new drug called AZD4547.
Growth factors are natural body chemicals that control cell growth. They work by binding to receptors, on the surface of cancer cells. This sends a signal to the inside of the cell, which sets off a chain of chemical reactions. AZD4547 is a type of biological therapy that works by blocking the receptor and stopping the signal from a growth factor called fibroblast growth factor (FGF). Drugs that block growth factor signals can stop cancer cells growing and dividing.
The aims of the trial are to
You could enter the 1st part of the trial if you had a that has lots of copies of genes called FGFR1 or FGFR2 (the doctors will check this using a test called FISH).
You can enter the next part of the trial if you have a type of non small cell lung cancer called squamous cell cancer and your tumour has a lot of copies of the FGFR1 gene, or you have cancer of the stomach or cancer at the junction where the stomach meets the oesophagus (gastro oesophageal junction cancer) and your tumour has a lot of copies of the FGFR2 gene.
And as well as the above, for all parts of the trial you
You cannot enter this trial if you
This is a phase 1 trial. In the 1st part of the trial, the researchers worked out the best dose of AZD4547. The trial then went on to recruit 40 people who have squamous cell lung cancer, stomach cancer or gastro oesophageal cancer. This part of the trial is to learn more about AZD4547 and to see if it might help people who have advanced cancer with certain genetic changes.
Before you join this part of the study, the trial team will get a sample of your tumour that was removed when you had surgery or a . If there isn't a sample available, they will ask you to have a biopsy.
AZD4547 is a tablet. You take it twice a day. As long as you don’t have any bad side effects, you can carry on taking it for as long as it helps you.
The trial team will ask you to take part in some optional extra studies. These include
The trial team will also ask your permission to take some extra blood samples that they can use to study your DNA to learn more about how genes can affect the way people respond to this drug and the side effects they may have.
If you won’t want to give these extra samples for research, or have any of the extra tests listed above, you don’t have to. You can still take part in the main trial.
You will see the trial doctors and have some tests before you start treatment. The tests include
You go to hospital once a week during the first 3 weeks of treatment. After that, you go to hospital for tests once every 3 weeks. The trial doctors will give you more information about which tests you will have each time and how long the visits are likely to take.
After you finish treatment you see the trial doctors again, and have more blood tests and an ECG.
As AZD4547 is a new drug, there may be some side effects we don’t know about yet. The possible side effects that researchers already know about include
Your doctor will advise you to avoid or limit certain foods or supplements during the trial as they can affect how AZD4547 works. This includes grapefruit and Seville oranges.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Malcolm Ranson
AstraZeneca
Experimental Cancer Medicine Centre (ECMC)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.